nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda has one key item — indulging Mrs. Pharmalot, who marks an important notch on the calendar. Otherwise, we plan to keep things simple by reading and snoozing, when possible. And what about you? You could go on a treasure hunt and visit garage sales. Perhaps your garden needs tending. Or you could take the opportunity to try something completely different. Well, whatever you do, have a grand time. But be safe. Oh, and one more thing — if this applies, remember to call mom …

AstraZeneca says that a trial of its Imfinzi immunotherapy drug lowered the risk of stage 3 lung cancer from worsening or causing death, Reuters reports. The results, which lifted AstraZeneca stock Friday morning, give the company a needed boost in the heated immunotherapy field as analysts noted there is a gap in the market for such a treatment. The drug was tested on patients who had not responded to conventional chemotherapy.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ah, “the phantom recall” of Motrin – it stirs memories of past glories on the Pharmalot! And about how long our sribe has been pursuing Pharma.
    “In May 2010, when Goggins appeared before a congressional committee investigating the “phantom recall,” she testified that she was not aware of the behavior of the contractors (Silverman, 2010) and that she had “no knowledge of instructions to contractors involved in the phantom recall to not tell store employees what they were doing.”
    url: http://open.lib.umn.edu/exploringbusiness/chapter/2-2-the-individual-approach-to-ethics/

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.